Skip to main content
. 2023 Sep 22;14:1263618. doi: 10.3389/fphar.2023.1263618

TABLE 3.

Baseline characteristics of patients with positive multi-drug resistant organisms.

AMS Pre-AMS p-value
MDRO infections 58 (11.03) 90 (18.48) <0.001
Sex (male), n (%) 23 (36.7) 38 (42.2) 0.864
Age (mean, IQR), years 62.5 (53.75–72) 61.5 (50–71) 0.560
ICU stay (mean, IQR), days 11 (9–17) 11.5 (7–16) 0.780
Underlying disease, n (%)
Diabetes mellitus 14 (24.1) 9 (10.0) 0.035
Metastatic cancer 0 (0) 1 (1.1) 1
Liver cirrhosis 3 (5.17) 5 (5.56) 1
Chronic kidney disease 6 (10.3) 5 (5.6) 0.341
Hypoproteinemia 35 (60.3) 49 (84.5) 0.501
MDRO, n (%)
Acinetobacter baumannii 11 (18.97) 23 (25.56) 0.425
Klebsiella pneumoniae 37 (63.79) 73 (81.11) 0.022
Pseudomonas aeruginosa 6 (10.34) 9 (10.00) 1
MRSA 8 (13.8) 8 (8.9) 0.421
Others 5 (8.62) 1 (1.11) 0.034
Infection site (presumed or confirmed)
Respiratory 54 (93.1) 78 (86.7) 0.283
Urinary tract 4 (6.9) 9 (10.0) 0.569
Intracranial 0 (0) 6 (6.67) 0.082
Disease severity
Sepsis 8 (13.8) 4 (4.4) 0.062
Septic shock 4 (6.9) 0 (0) 0.022
APACHE Ⅱ, mean (SD) 24.60 ± 7.71 22.71 ± 5.41 0.081

MDRO: Multi-drug resistant organism; MRSA: Methicillin-resistant Staphylococcus aureus.